Literature DB >> 31060803

Dopamine D1 and D2 Receptors Differentially Regulate Rac1 and Cdc42 Signaling in the Nucleus Accumbens to Modulate Behavioral and Structural Plasticity After Repeated Methamphetamine Treatment.

Genghong Tu1, Li Ying1, Liuzhen Ye1, Jinlan Zhao1, Nuyun Liu2, Juan Li3, Yutong Liu1, Mengjuan Zhu1, Yue Wu1, Bin Xiao1, Huidong Guo1, Fukun Guo4, Huijun Wang5, Lin Zhang6, Lu Zhang7.   

Abstract

BACKGROUND: Methamphetamine (METH) is a highly addictive psychostimulant that strongly activates dopamine receptor signaling in the nucleus accumbens (NAc). However, how dopamine D1 and D2 receptors (D1Rs and D2Rs, respectively) as well as downstream signaling pathways, such as those involving Rac1 and Cdc42, modulate METH-induced behavioral and structural plasticity is largely unknown.
METHODS: Using NAc conditional D1R and D2R deletion mice, Rac1 and Cdc42 mutant viruses, and a series of behavioral and morphological methods, we assessed the effects of D1Rs and D2Rs on Rac1 and Cdc42 in modulating METH-induced behavioral and structural plasticity in the NAc.
RESULTS: D1Rs and D2Rs in the NAc consistently regulated METH-induced conditioned place preference, locomotor activation, and dendritic and spine remodeling of medium spiny neurons but differentially regulated METH withdrawal-induced spatial learning and memory impairment and anxiety. Interestingly, Rac1 and Cdc42 signaling were oppositely modulated by METH, and suppression of Rac1 signaling and activation of Cdc42 signaling were crucial to METH-induced conditioned place preference and structural plasticity but not to locomotor activation. D1Rs activated Rac1 and Cdc42 signaling, while D2Rs inhibited Rac1 signaling but activated Cdc42 signaling to mediate METH-induced conditioned place preference and structural plasticity but not locomotor activation. In addition, NAc D1R deletion aggravated METH withdrawal-induced spatial learning and memory impairment by suppressing Rac1 signaling but not Cdc42 signaling, while NAc D2R deletion aggravated METH withdrawal-induced anxiety without affecting Rac1 or Cdc42 signaling.
CONCLUSIONS: D1Rs and D2Rs differentially regulate Rac1 and Cdc42 signaling to modulate METH-induced behavioral plasticity and the structural remodeling of medium spiny neurons in the NAc.
Copyright © 2019 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Behavioral plasticity; Cdc42; Dopamine D(1) and D(2) receptors; Methamphetamine; Nucleus accumbens; Rac1; Structural plasticity

Mesh:

Substances:

Year:  2019        PMID: 31060803     DOI: 10.1016/j.biopsych.2019.03.966

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

1.  A novel microRNA, novel-m009C, regulates methamphetamine rewarding effects.

Authors:  Li Zhu; Feifei Wu; Zhilan Yan; Lijun He; Shufei Wang; Haohao Hu; Eyleen L K Goh; Yingjie Zhu; Fanglin Guan; Teng Chen
Journal:  Mol Psychiatry       Date:  2022-06-17       Impact factor: 15.992

2.  Dopamine modulates visual threat processing in the superior colliculus via D2 receptors.

Authors:  Quentin Montardy; Zheng Zhou; Lei Li; Qingning Yang; Zhuogui Lei; Xiaolong Feng; Shanping Chen; Qianqian Shi; Huiqi Zhang; Shuran Chen; Zhijian Zhang; Binghao Zhao; Fuqiang Xu; Zhonghua Lu; Liping Wang
Journal:  iScience       Date:  2022-05-11

3.  Silencing the Tlr4 Gene Alleviates Methamphetamine-Induced Hepatotoxicity by Inhibiting Lipopolysaccharide-Mediated Inflammation in Mice.

Authors:  Li-Bin Wang; Li-Jian Chen; Qi Wang; Xiao-Li Xie
Journal:  Int J Mol Sci       Date:  2022-06-18       Impact factor: 6.208

4.  Knockout of Dopamine D3 Receptor Gene Blocked Methamphetamine-Induced Distinct Changes of Dopaminergic and Glutamatergic Synapse in the Nucleus Accumbens Shell of Mice.

Authors:  Shuai Wang; Ming Li; Linlan Su; Yu Wang; Dongliang Ma; Hongyan Wang; Jie Zhu; Teng Chen
Journal:  Front Cell Neurosci       Date:  2022-05-30       Impact factor: 6.147

5.  Decreased Neuronal Excitability in Medial Prefrontal Cortex during Morphine Withdrawal is associated with enhanced SK channel activity and upregulation of small GTPase Rac1.

Authors:  Liang Qu; Yuan Wang; Yang Li; Xin Wang; Nan Li; Shunnan Ge; Jing Wang; Gene-Jack Wang; Nora D Volkow; Bing Lang; Ping Wang; Hao Wu; Jie Zeng; Jian Fu; Jiaming Li; Yue Zhang; Xuelian Wang
Journal:  Theranostics       Date:  2020-06-05       Impact factor: 11.556

Review 6.  The Role of Rac GTPase in Dendritic Spine Morphogenesis and Memory.

Authors:  Joana Freitas Costa; Monica Dines; Raphael Lamprecht
Journal:  Front Synaptic Neurosci       Date:  2020-04-17

7.  Mice carrying a schizophrenia-associated mutation of the Arhgap10 gene are vulnerable to the effects of methamphetamine treatment on cognitive function: association with morphological abnormalities in striatal neurons.

Authors:  Kazuhiro Hada; Bolati Wulaer; Taku Nagai; Norimichi Itoh; Masahito Sawahata; Akira Sobue; Hiroyuki Mizoguchi; Daisuke Mori; Itaru Kushima; Toshitaka Nabeshima; Norio Ozaki; Kiyofumi Yamada
Journal:  Mol Brain       Date:  2021-01-22       Impact factor: 4.041

8.  Pharmacological and Genetic Evidence of Dopamine Receptor 3-Mediated Vasoconstriction in Isolated Mouse Aorta.

Authors:  Veronica Zingales; Sebastiano Alfio Torrisi; Gian Marco Leggio; Claudio Bucolo; Filippo Drago; Salvatore Salomone
Journal:  Biomolecules       Date:  2021-03-11

9.  Regulation of Cdc42 signaling by the dopamine D2 receptor in a mouse model of Parkinson's disease.

Authors:  Li Ying; Jinlan Zhao; Yingshan Ye; Yutong Liu; Bin Xiao; Tao Xue; Hangfei Zhu; Yue Wu; Jing He; Sifei Qin; Yong Jiang; Fukun Guo; Lin Zhang; Nuyun Liu; Lu Zhang
Journal:  Aging Cell       Date:  2022-04-12       Impact factor: 11.005

Review 10.  Synergistic Impairment of the Neurovascular Unit by HIV-1 Infection and Methamphetamine Use: Implications for HIV-1-Associated Neurocognitive Disorders.

Authors:  Nikolai Fattakhov; Silvia Torices; Michael Stangis; Minseon Park; Michal Toborek
Journal:  Viruses       Date:  2021-09-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.